切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2017, Vol. 11 ›› Issue (20) : 2335 -2339. doi: 10.3877/cma.j.issn.1674-0785.2017.20.009

所属专题: 文献

综述

慢性血栓栓塞性肺动脉高压治疗的新进展
王凤1, 胡晓芸1,(), 张叶钦1   
  1. 1. 030001 太原,山西医科大学第一医院呼吸科
  • 收稿日期:2017-02-23 出版日期:2017-10-15
  • 通信作者: 胡晓芸

New progress in treatment of chronic thromboembolic pulmonary hypertension

Feng Wang1, Xiaoyun Hu1,(), Yeqin Zhang1   

  1. 1. Department of Respiratory Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2017-02-23 Published:2017-10-15
  • Corresponding author: Xiaoyun Hu
  • About author:
    Corresponding author: Hu Xiaoyun, Email:
引用本文:

王凤, 胡晓芸, 张叶钦. 慢性血栓栓塞性肺动脉高压治疗的新进展[J]. 中华临床医师杂志(电子版), 2017, 11(20): 2335-2339.

Feng Wang, Xiaoyun Hu, Yeqin Zhang. New progress in treatment of chronic thromboembolic pulmonary hypertension[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(20): 2335-2339.

慢性血栓栓塞性肺动脉高压(CTEPH)是一种自然预后不佳的渐进性肺血管疾病,肺动脉内膜剥脱术是目前治疗CTEPH的首选方案,甚至有治愈的可能;但30%~50%的患者因远端血管病变或严重合并症而无法手术,靶向药物和球囊肺动脉成形术的发展为这些患者的治疗带来了新的曙光。本文对CTEPH治疗的最新研究进行论述。

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor prognosis if not treated. Pulmonary endarterectomy is currently the standard of treatment as it is potentially curative. However, 30%-50% of patients is inoperable due to either distal pulmonary vascular obstruction or significant comorbidities. The development of targeted drugs and balloon pulmonary angioplasty has brought a new dawn to these patients. This paper discusses the latest research on the treatment of CTEPH.

图1 CTEPH患者规范化治疗流程
[1]
Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding [J]. Eur Respir J, 2013, 41(2): 462-468.
[2]
Lau EM, Tamura Y, MeGoon MD, et al. The 2015ESC/ERS Guidelines for the diagnosis and reatment of pulmonary hypertension: a practical chronicle of progress [J]. Eur Respir J, 2015, 46(4): 879-882.
[3]
D′Armini AM, Morsolini M, Mattiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension [J]. J Thorac Cardiovasc Surg, 2014, 148(3): 1005-1012; e1-2.
[4]
Mazurek A, Dziuk M, Witkowska-Patena E, et al. The utility of hybrid SPECT/CT lung perfusion scintigraphy in pulmonary embolism diagnosis [J]. Respiration, 2015, 90(5): 393-401.
[5]
Callahan J, Hofman MS, Siva S, et al. High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated(4-D) PET/CT [J]. Eur J Nucl Med Mol Imaging, 2014, 41(2): 343-349.
[6]
Nierlich P, Hold A, Ristl R. Outcome after surgical treatment of chronic thromboembolic pulmonary hypertension: dealing with different patient subsets. A single-centre experience [J]. Eur J Cardiothorac Surg, 2016, 50(5): 898-906.
[7]
López Gude MJ, Pérez de la Sota E, Forteza Gil A, et al. Pulmonary Thrombo endarterectomy in 106 Patients With Chronic Thromboembolic Pulmonary Hypertension [J]. Arch Bronconeumol, 2015, 28: 300-304.
[8]
Rolf A, Rixe J, Kim WK, et al. Pulmonary vascular remodeling before and after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a cardiac magnetic resonance study [J]. Int J Cardiovasc Imaging, 2015, 31: 613-619.
[9]
Ben-Dov I, Kogan A, Preisman S, et al. Chronic thromboembolic pulmonary hypertension: can successful thrombendarterectomy normalize exercise capacity and gas exchange? [J]. Harefuah, 2012, 151(2): 74-78, 128-129.
[10]
Nagel C, Prange F, Guth S, et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension [J]. PLoS One, 2012, 7(7): e41603.
[11]
Ghofrani HA, D'Armini AM, Grimminger F, et al. CHEST-1 study group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension [J]. N Engl J Med, 2013, 369: 319-329.
[12]
Simonneau G, D′Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) [J]. Eur Respir J, 2015, 45: 1293-1302.
[13]
Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial [J]. Lancet Respir Med, 2016, 4(5): 361-371.
[14]
Jaïs X, D′Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT(Bosentan effects in iNopErable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial [J]. J Am Coll Cardiol, 2008, 52(25): 2127-2134.
[15]
Nishikawa-Takahashi M, Ueno S, Kario K. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension [J]. Life Sci, 2014, 118(2): 410-413.
[16]
Abe S, Ishida K, Masuda M, et al. A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy [J]. Gen Thorac Cardiovasc Surg, 2017, 65(3):153-159.
[17]
Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension [J]. Chest, 2008, 134: 229-236.
[18]
Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension [J]. J Thorac Cardiovasc Surg, 2010, 139: 85-91.
[19]
Surie S, Reesink HJ, Marcus JT, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol, 2013, 36: 698-703.
[20]
Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension(CTEPH): results from an international prospective registry [J]. Circulation, 2011, 124: 1973-1981.
[21]
Ishiguro H, Kataoka M, Inami T, et al. Percutaneous transluminal pulmonary angioplasty for central-type chronic thromboembolic pulmonary hypertension [J]. JACC Cardiovasc Interv, 2013, 6(11): 1212-1213.
[22]
Kawakami T, Ogawa A, Miyaji K, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty [J]. Circ Cardiovasc Interv, 2016, 9(10): e003318.
[23]
Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty [J]. Eur Respir J, 2014, 43: 1394-1402.
[24]
Taniguchi Y, Miyagawa K, Nakayama K, et al. Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension [J]. Euro Intervention, 2014, 10(4): 518-525.
[25]
Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension [J]. Heart, 2013, 99(19): 1415-1420.
[26]
Tatebe S, Sugimura K, Aoki T, et al. Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension [J]. Circ J, 2016, 80(4): 980-988.
[27]
Inami T, Kataoka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheterinterventional therapy for chronic thromboembolic pulmonary hypertension [J]. JACC Cardiovasc Interv, 2014, 7: 1297-1306.
[28]
Inagaki T, Terada J, Tanabe N, et al. Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study [J]. Respir Investig, 2014, 52: 357-364.
[29]
Ivarsson B, Ekmehag B, Hesselstrand R. et al. Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertensionor chronic thromboembolic pulmonary hypertension [J]. Clin Med Insights Circ Respir Pulm Med, 2014, 8: 21-28.
[30]
王平生,刘晓静,孙尚帛, 等. 中西医结合治疗慢性肺血栓栓塞性肺动脉高压30例临床研究 [J]. 江苏中医药, 2016, 48(6): 28-30.
[1] 中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会. 结直肠癌靶向治疗中国专家共识[J]. 中华普通外科学文献(电子版), 2023, 17(01): 1-8.
[2] 鲁旭, 张英才, 李华, 赵辉, 李海波, 张剑文, 邱春辉, 易述红, 汪根树, 张剑, 杨扬, 陈规划, 汪国营. 使用程序性死亡受体-1单克隆抗体治疗肝癌肝移植术后复发的临床策略[J]. 中华移植杂志(电子版), 2021, 15(06): 334-340.
[3] 努尔艾力·排尔哈提, 展昭兴, 王令令, 张古田, 朱新胜. 肾癌合并静脉癌栓的诊疗进展[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(05): 459-462,471.
[4] 翟官忠, 刘泽林, 王清华, 柯帅, 郭佳. 肾癌肾部分切除术后局部复发的临床分析[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 128-132.
[5] 罗标, 姜福全, 刘鑫, 李宏岩. 腹腔镜治疗双原发膀胱癌及乙状结肠癌一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(03): 258-259.
[6] 李文洁, 金发光, 袁灿亮, 陈艳丽. 同步推量调强放疗联合靶向药物治疗晚期非小细胞肺癌的临床效果[J]. 中华肺部疾病杂志(电子版), 2020, 13(04): 507-509.
[7] 中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会. 结直肠癌靶向治疗中国专家共识[J]. 中华结直肠疾病电子杂志, 2022, 11(05): 353-360.
[8] 邢宝才, 徐达. 从NCCN指南更新看靶向药物在结直肠癌肝转移新辅助治疗中的地位[J]. 中华结直肠疾病电子杂志, 2018, 07(03): 202-206.
[9] 庄永泽. 肿瘤相关性急性肾损伤的研究进展[J]. 中华肾病研究电子杂志, 2019, 08(04): 150-154.
[10] 叶家欣, 丁一, 陈成, 陈涛, 陆立冲, 葛敏. 体外膜肺氧合在慢性血栓栓塞性肺动脉高压患者血栓内膜剥脱术围术期的应用[J]. 中华重症医学电子杂志, 2018, 04(03): 275-280.
[11] 王金志, 陶新曹, 谢万木, 傅志辉, 赵蕴伟, 黄强, 翟振国. 球囊肺动脉成形术在慢性血栓栓塞性肺动脉高压治疗中的进展[J]. 中华介入放射学电子杂志, 2023, 11(03): 262-267.
[12] 魏胜超, 邓堂, 廖勇, 金桂云, 王剑锋. 慢性血栓栓塞性肺动脉高压的治疗[J]. 中华介入放射学电子杂志, 2020, 08(04): 378-381.
[13] 周阳逸, 顾建平, 汪涛. 球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压的现状[J]. 中华介入放射学电子杂志, 2020, 08(02): 184-188.
[14] 何泓锦, 马和平, 苏俐. 分子靶向药物联合TACE在肝癌治疗中的进展[J]. 中华介入放射学电子杂志, 2015, 03(04): 222-225.
阅读次数
全文


摘要